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During the last two decades, the use of ﬂuoro-
quinolones has increased enormously in practi-
cally all the institutions of the developed world.
The use of this group of drugs is even greater
outside hospitals where they are one of the more
commonly prescribed agents for community-
acquired infections.
The present supplement to Clinical Microbiology
and Infection reviews the more common indica-
tions for clinical use of ﬂuoroquinolones, their
immediate challenges and prospects for the
future.
Modern ﬂuoroquinolones are among the most
commonly selected group of agents for the ther-
apy of community-acquired pneumonia. The art-
icle by Carratala´ et al. reviews the role of
ﬂuoroquinolones in CAP, highlighting the wide
spectrum of activity of these drugs against
many respiratory tract pathogens, including
Streptococcus pneumoniae and other microorgan-
isms of the so called atypical pneumonia group.
Fluoroquinolones are active against the over-
whelming majority of isolates of S. pneumoniae
including strains resistant to penicillin and other
multiresistant strains as discussed in the article by
File et al.
Cunha reviews the present role of atypical
microorganisms as etiologic agents of pneumonia,
in different age groups while Yu et al. compare
the potential value of ﬂuoroquinolones and
macrolides in the treatment of legionnaire’s dis-
ease. Quinolones are probably the agents of
choice, at present, for the treatment of infections
caused by microorganisms belonging to the genus
Legionella, as the experience in recent outbreaks
suggests.
Mensa and Trilla review in their article the
indications for antimicrobial therapy in patients
with acute exacerbation of chronic bronchitis and
the evidence in favour of the use of ﬂuoroquino-
lones in some of those patients.
The issues regarding the relationship between
the use and misuse of ﬂuoroquinolones and the
development of resistance to S. pneumoniae are
discussed in depth by Garcı´a-Rey et al.
Use of ﬂuoroquinolones in nonrespiratory
infections also deserves a considerable amount
of space in this issue. Wagenlehner and Naber
discuss the difﬁcult issue of bacterial prostatitis
and with their extensive experience they provide
an interesting insight into the appropriate use of
ﬂuoroquinolones in prostatitis.
Another very interesting topic is the use of
ﬂuoroquinolones in patients with osteoarticular
infections and this is reviewed by Barbera´n et al.
Fluorquinolones are, at present, among the more
commonly used drugs for the treatment of bone
and joint infections. This is due to their spectrum
of in-vitro activity, bone penetration and conveni-
ence of use for the patients. The oral bioavailabil-
ity of the drug and good tolerance allow for very
prolonged periods of oral and home-based ther-
apy.
Finally, levoﬂoxacin is establishing a niche as
an agent of potential use in selected cases of
patients with severe pneumonia admitted to
Intensive Care Units which includes certain
patients with ventilator-associated pneumonia.
This context is elegantly reviewed by Alvarez-
Lerma et al.
This issue reﬂects the opinions of different
authors from both the USA and Europe to
whom I am grateful for their contributions. I
sincerely hope that the readers of CMI enjoy the
information and ﬁnd it attractive and stimula-
ting.
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